EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling

Weijie Zhang iD, Adam M Lee iD, Sampreeti Jena, Yingbo Huang iD, Yeung Ho, Kiel T Tietz iD, Conor R Miller iD, Mei-Chi Su iD, Joshua Mentzer, Alexander L Ling, Yingming Li, Scott M Dehm und 1 weitere

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2218522120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Weijie Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, MN 55455. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute, UMN | Clinical and Translational Science Institute, University of Minnesota.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of cancer deaths in US men. Many PC cases metastasize and develop resistance to systemic hormonal therapy, a stage known as castration-resistant prostate cancer (CRPC). Therefore, there is an urgent need to develop effective therapeutic strategies for CRPC. Traditional drug discovery pipelines require significant time and capital input, which highlights a need for novel methods to evaluate the repositioning potential of existing drugs. Here, we present a computational framework to predict drug sensitivities of clinical CRPC tumors to various existing compounds and identify treatment options with high potential for clinical impact. We applied this method to a CRPC patient cohort and nominated drugs to combat resistance to hormonal therapies including abiraterone and enzalutamide. The utility of this method was demonstrated by nomination of multiple drugs that are currently undergoing clinical trials for CRPC. Additionally, this method identified the tetracycline derivative COL-3, for which we validated higher efficacy in an isogenic cell line model of enzalutamide-resistant vs. enzalutamide-sensitive CRPC. In enzalutamide-resistant CRPC cells, COL-3 displayed higher activity for inhibiting cell growth and migration, and for inducing G1-phase cell cycle arrest and apoptosis. Collectively, these findings demonstrate the utility of a computational framework for independent validation of drugs being tested in CRPC clinical trials, and for nominating drugs with enhanced biological activity in models of enzalutamide-resistant CRPC. The efficiency of this method relative to traditional drug development approaches indicates a high potential for accelerating drug development for CRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansNitrilesDrug DiscoveryCastrationDrug Resistance, NeoplasmReceptors, AndrogenBenzamidesPhenylthiohydantoinTetracyclines

Stichwörter der Autor:innen

castration-resistant prostate cancerdrug discoverydrug repurposedrug response predictionenzalutamide

Substanzen

NitrilesReceptors, AndrogenenzalutamideBenzamidesPhenylthiohydantointetracycline CMT-3Tetracyclines

Autor:innen und Institutionen

  • Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, MN 55455.
  • The Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455.
  • Department of Laboratory Medicine and Pathology, The University of Minnesota Medical School, Minneapolis, MN 55455.

ORCID-Profile: Weijie Zhang, Adam M Lee, Yingbo Huang, Kiel T Tietz, Conor R Miller, Mei-Chi Su, R Stephanie Huang

Förderung

  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute
  • UMN | Clinical and Translational Science Institute, University of Minnesota
  • UMN | Graduate School, University of Minnesota
  • University of Minnesota

Zitieren

APA

Zhang, W., Lee, A. M., Jena, S., Huang, Y., Ho, Y., Tietz, K. T., Miller, C. R., Su, M. C., Mentzer, J., Ling, A. L., Li, Y., Dehm, S. M., & Huang, R. S. (2023). Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2218522120

Vancouver

Zhang W, Lee AM, Jena S, Huang Y, Ho Y, Tietz KT, et al. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2218522120

BibTeX
@article{Zhang2023,
  author = {Zhang, Weijie and Lee, Adam M and Jena, Sampreeti and Huang, Yingbo and Ho, Yeung and Tietz, Kiel T and Miller, Conor R and Su, Mei-Chi and Mentzer, Joshua and Ling, Alexander L and Li, Yingming and Dehm, Scott M and Huang, R Stephanie},
  title = {Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2218522120}
}
Kostenlos starten →